Ask AI

Transforming Lymphoma Management: Practical Integration of CAR T Cell Therapies for Improved Outcomes

Video
This activity is available for 1.00 CME/CE credit(s).

Released: October 12, 2026

Expiration: April 11, 2027

See Activity Collection

In this on-demand webcast, experts review the evolving role of CAR T-cell therapy across B-cell malignancies, including the underlying principles of autologous CAR T-cell treatment, currently approved products, and clinical trial data supporting their use in large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia/small lymphocytic lymphoma. The faculty also discuss practical considerations for integrating CAR T-cell therapy into clinical care, including timely referral to authorized treatment centers, patient selection, bridging therapy, coordination between community and academic teams, and inpatient vs outpatient treatment approaches. In addition, the webcast addresses recognition and management of acute and delayed toxicities, including cytokine release syndrome, ICANS, cytopenias, hypogammaglobulinemia, and infection risk, as well as prophylaxis and long-term monitoring strategies. Emerging approaches, including dual-targeting CAR T-cell constructs and rapid-manufacturing strategies, are also highlighted, underscoring how current evidence and evolving best practices can inform treatment selection, referral, toxicity management, and longitudinal care.

CAR T Cell Therapies for Improved Outcomes

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with B-cell lymphomas do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

After demonstrating high ORR and CR, lisocabtagene maraleucel is now approved by the FDA for the treatment of what adult patient population?

4.

68-Yr-Old Woman With R/R CLL



  • A 68-yr-old woman was diagnosed with CLL in 2016

    • She has high-risk cytogenetics with del(17p)



  • She was initially treated with ibrutinib with a PR

    • After 3 yr, she has increasing lymphocytosis and new lymphadenopathy



  • She then completed 24 mo of venetoclax treatment

    • Maintained CR for 1 yr, but now has further disease progression



Based on current indications, which CAR T-cell therapy is the most appropriate treatment option for this patient? 

5.

CRS After CAR T-Cell Infusion



  • A 70-yr-old man received axicabtagene ciloleucel infusion for R/R LBCL

  • 48 hr after infusion, he developed fever, dizziness, and shortness of breath

  • He required vasopressor support as well as high-flow nasal cannula

  • Additional workup, including lab tests and imaging, were not suggestive of acute infection 

In addition to supportive care with a vasopressor and high-flow nasal cannula, what is the most appropriate treatment to manage his grade 3 CRS?

6.

Prophylaxis is routinely recommended for which of the following conditions for all patients after CAR T-cell therapy?